9MSY image
Entry Detail
PDB ID:
9MSY
EMDB ID:
EMD-48591
Keywords:
VIRAL PROTEIN/IMMUNE SYSTEM
Title:
G002-480-0546 Fab in complex with V703-0537_T278M_L14 SOSIP and BG18 Fab
Biological Source:
Source Organism:
Human immunodeficiency virus 1, Homo sapiens
Host Organism:
Homo sapiens
PDB Version:
Deposition Date:
2025-01-10
Release Date:
2025-05-28
Method Details:
Experimental Method:
ELECTRON MICROSCOPY
Resolution:
3.40 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
9MSY validation report
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:V703-0537_T278M_L14 SOSIP
Chain IDs:A, F (auth: B), K (auth: C)
Chain Length:654
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Description:BG18 Fab heavy chain
Chain IDs:B (auth: G), G (auth: J), L (auth: O)
Chain Length:233
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:G002-480-0546 Fab heavy chain
Chain IDs:E (auth: H), J (auth: K), O (auth: P)
Chain Length:226
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:BG18 Fab light chain
Chain IDs:C (auth: I), H (auth: M), M (auth: Q)
Chain Length:214
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:G002-480-0546 Fab light chain
Chain IDs:D (auth: L), I (auth: N), N (auth: R)
Chain Length:211
Number of Molecules:3
Biological Source:Homo sapiens
Ligand Molecules
NAG
Primary Citation
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans.
Willis, J.R, Prabhakaran, M, Muthui, M, Naidoo, A, Sincomb, T, Wu, W, Cottrell, C.A, Landais, E, deCamp, A.C, Keshavarzi, N.R, Kalyuzhniy, O, Lee, J.H, Murungi, L.M, Ogonda, W.A, Yates, N.L, Corcoran, M.M, Phulera, S, Musando, J, Tsai, A, Lemire, G, Sein, Y, Muteti, M, Alamuri, P, Bohl, J.A, Holman, D, Himansu, S, Leav, B, Reuter, C, Lin, L.A, Ding, B, He, C, Straus, W.L, MacPhee, K.J, Regadas, I, Nyabundi, D.V, Chirchir, R, Anzala, A, Kimotho, J.N, Kibet, C, Greene, K, Gao, H, Beatman, E, Benson, K, Laddy, D, Brown, D.M, Bronson, R, Baptiste, J, Gajjala, S, Rikhtegaran-Tehrani, Z, Benner, A, Ramaswami, M, Lu, D, Alavi, N, Amirzehni, S, Kubitz, M, Tingle, R, Georgeson, E, Phelps, N, Adachi, Y, Liguori, A, Flynn, C, McKenney, K, Zhou, X, Owuor, D.C, Owuor, S, Kim, S.Y, Duff, M, Kim, J.Y, Gibson, G, Baboo, S, Diedrich, J, Schiffner, T, Shields, M, Matsoso, M, Santos, J, Syvertsen, K, Kennedy, A, Schroeter, M, Vekemans, J, Yates, J, Paulson, J.C, Hyrien, O, McDermott, A.B, Maenetje, P, Nyombayire, J, Karita, E, Ingabire, R, Edward, V, Muturi-Kioi, V, Maenza, J, Shapiro, A.E, McElrath, M.J, Edupuganti, S, Taylor, B.S, Diemert, D, Ozorowski, G, Koup, R.A, Montefiori, D, Ward, A.B, Hedestam, G.K, Tomaras, G, Hunt, D.J, Muema, D, Sok, D, Laufer, D.S, Andrews, S.F, Nduati, E.W, Schief, W.R.Show
Science ? eadr8382 eadr8382 (2025)
PMID: 40373112 DOI: 10.1126/science.adr8382

Abstact

A leading HIV vaccine strategy requires a priming immunogen to induce broadly neutralizing antibody (bnAb) precursors, followed by a series of heterologous boosters to elicit somatic hypermutation (SHM) and produce bnAbs. In two randomized, open-label phase 1 human clinical trials, IAVI-G002 in the United States and IAVI-G003 in Rwanda and South Africa, we evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens (both trials) and first-boosting immunogens (IAVI-G002). The vaccines were generally safe and well tolerated, except 18% of IAVI-G002 participants experienced skin reactions. Priming induced bnAb precursors with substantial frequencies and SHM, and heterologous boosting elicited increased SHM, affinity, and neutralization activity toward bnAb development. The results establish clinical proof of concept that heterologous boosting can advance bnAb-precursor maturation and demonstrate bnAb priming in Africa where the HIV burden is highest.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
9MSY